Cooley M&A
JANUARY 22, 2025
While global M&A deal value across sectors remained relatively flat overall , pharmaceuticals and life sciences M&A in 2024 dipped relative to the prior year. Indeed, the largest US biotech exit in 2024 was Vertex Pharmaceuticals $4.9 Immunology deals stood out, including Vertex Pharmaceuticals $4.9 from 2023. [1]
CNBC: Investing
JUNE 9, 2025
Cardinal Health Josh — All three major Pharmaceutical Wholesalers made the list - McKesson (MCK) , Cencora (COR) and Cardinal Health (CAH) , only Cardinal looks good technically right now: CAH held its 50-day on a weekly closing basis during the April bloodbath, I'd use that area as a stop and update it each week.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
M&A Leadership Council
AUGUST 15, 2022
For example, in Switzerland, Sandoz and Ciba spun off their chemicals business units – one as a taxable initial public offering and one as a tax-free “demerger” – before merging their pharmaceutical cores into Novartis. If the parent retains an interest in an IPO carve-out, this may be termed a “divestiture IPO.”.
Cooley M&A
JANUARY 25, 2023
But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions. Let’s dig in.
Cooley M&A
JANUARY 23, 2024
While the year saw an overall decline in M&A activity (down 17% from 2022) , total pharmaceuticals and life sciences deal value in 2023 increased by approximately 50% compared to 2022. Why did life sciences outperform the market? The last quarter of the year ended with a surge of deal activity.
Peak Frameworks
SEPTEMBER 19, 2023
For example, in the 2012 Facebook IPO, common shareholders gained exposure to the tech giant's fortunes, while also securing a say in corporate matters. By virtue of their ownership, they possess a direct financial interest in the company's success.
Mergers and Inquisitions
NOVEMBER 1, 2023
Advanced Financial Modeling : There’s a case study on Jazz Pharmaceuticals if you’re more interested in that vertical. What about when the IPO market is shut down and exits look uncertain? Life science-oriented roles in VC and growth firms will also be fine because there’s always demand for new biotech and pharmaceutical products.
Expert insights. Personalized for you.
Let's personalize your content